In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BioMarin and Daiichi develop PKU therapeutic Phenoptin

Executive Summary

Daiichi Suntory Pharma and BioMarin Pharmaceutical (therapeutics for serious pediatric diseases) are collaborating to develop Phenoptin (6R-BH4), BioMarin's oral formulation of the naturally occurring enzyme cofactor tetrahydrobiopterin, to treat phenylketonuria (PKU), a genetic disease in evidence within moments after birth.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • R&D and Marketing (Licensing)

Related Companies